Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age

By Rose C.  

Breast Cancer Research and Treatment, Vol. 61, Iss. 2, 2000-05 ,pp. : 103-110

Springer Publishing Company

Access to resources Recommend Favorite

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 135-136

Informa Healthcare

Access to resources Recommend Favorite

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months

By Buzdar A.  

Breast Cancer Research and Treatment, Vol. 77, Iss. 3, 2003-02 ,pp. : 295-295

Springer Publishing Company

Access to resources Recommend Favorite

Anastrozole (Arimidex(TM)) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

By Nabholtz J.M.   Bonneterre J.   Buzdar A.   Robertson J.F.R.   Thurlimann B.   for the Arimidex Writing Committee on behalf of the Investigators  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1684-1689

Elsevier

Access to resources Recommend Favorite

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

By Carlson Robert  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1049-1056

Springer Publishing Company

Access to resources Recommend Favorite